adenosine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 14 (58.33) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Fathi, M; Hajibeygi, R; Jazi, K; Klegeris, A; McElhinney, A; Sayehmiri, F; Shool, S; Sodeifian, F; Tavasol, A; Tavirani, MR; Vakili, K; Yaghoobpoor, S | 1 |
| Jamwal, S; Kumar, P | 1 |
| Kumar, P; Singh, S | 1 |
| Bonaventura, J; Brugarolas, M; Casadó, V; Cellai, L; Chang, CP; Chern, Y; Cortés, A; Dettori, I; Ferré, S; Guitart, X; Narayanan, M; Orrú, M; Pedata, F; Rea, W | 1 |
| Isalan, M; Kutryb-Zajac, B; Mielcarek, M; Slominska, EM; Smolenski, RT; Toczek, M; Zukowska, P | 1 |
| Chen, CM; Chen, HM; Chern, Y; Kao, YH; Lai, HL; Lin, CJ; Lin, MS; Wu, YR | 1 |
| Bizzoco, E; Cipriani, S; Gianfriddo, M; Melani, A; Pedata, F; Vannucchi, MG | 1 |
| Chen, CM; Chen, HM; Chen, HW; Chern, Y; Chiang, MC; Chou, SY; Lai, HL; Tsai, FJ | 1 |
| Armida, M; Chiodi, V; Domenici, MR; Ferrante, A; Martire, A; Pézzola, A; Popoli, P; Potenza, RL | 1 |
| Chang, C; Chen, HM; Chen, JB; Chen, JF; Chen, WP; Chern, Y; Chiang, MC; Fang, JM; Huang, NK; Lai, HL; Lin, CI; Lin, CJ; Lin, JH; Lin, JT; Lin, YL; Liu, EM; Shen, YC; Wu, YS; Yang, CW | 1 |
| Bantubungi, K; Blum, D; d'Alcantara, P; Galas, MC; Gall, D; Schiffmann, SN | 1 |
| Bantubungi, K; Blum, D; Brouillet, E; Cuvelier, L; Galas, MC; Gall, D; Galluzzo, M; Ledent, C; Muller, CE; Pintor, A; Popoli, P; Rolland, AS; Schiffmann, SN | 1 |
| Blum, D; Galas, MC; Hourez, R; Popoli, P; Schiffmann, SN | 1 |
| Corsi, C; Gianfriddo, M; Melani, A; Pedata, F; Pèzzola, A; Popoli, P; Reggio, R | 1 |
| Alfinito, PD; Manzino, L; Rijhsinghani, S; Sonsalla, PK; Wang, SP; Zeevalk, GD | 1 |
| Gianfriddo, M; Giovannini, MG; Melani, A; Pedata, F; Turchi, D | 1 |
| Chao, MV; Lee, FS | 1 |
| Chang, C; Chang, HH; Chen, HM; Chern, Y; Chiang, MC; Chien, CL; Chou, SY; Lai, HL; Lee, YC; Lin, YS; Sun, CN; Tung, YY; Wang, SC; Wu, YC | 1 |
| Calamandrei, G; Domenici, MR; Felici, F; Lastoria, G; Martire, A; Popoli, P; Scattoni, ML; Tebano, MT | 1 |
| Boison, D | 1 |
| Caporali, MG; Pèzzola, A; Popoli, P; Reggio, R; Scotti de Carolis, A | 1 |
| Silkis, I | 1 |
| Sil'kis, IG | 1 |
| Martinez-Mir, MI; Palacios, JM; Probst, A | 1 |
6 review(s) available for adenosine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Kynurenic Acid; Kynurenine; NAD; Niacinamide; Parkinson Disease; Tryptophan | 2022 |
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review.
Topics: Acetylcholine; Adenosine; Animals; Basal Ganglia; Cannabinoids; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Huntington Disease; Neuropeptides; Parkinson Disease; Synaptic Transmission | 2019 |
Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Disease Models, Animal; Humans; Huntington Disease; Mitochondrial Diseases; Models, Molecular; Models, Neurological; Mutation; Neural Networks, Computer; Neuroprotective Agents; Receptor, Adenosine A1; Receptor, Adenosine A2A; Receptors, Dopamine | 2003 |
Adenosine as a neuromodulator in neurological diseases.
Topics: Adenosine; Adenosine Kinase; Alzheimer Disease; Animals; Brain Diseases; Brain Ischemia; Epilepsy; Humans; Huntington Disease; Pain; Parkinson Disease; Schizophrenia; Synaptic Transmission | 2008 |
The cortico-basal ganglia-thalamocortical circuit with synaptic plasticity. II. Mechanism of synergistic modulation of thalamic activity via the direct and indirect pathways through the basal ganglia.
Topics: Adenosine; Basal Ganglia; Cerebral Cortex; Dopamine; Humans; Huntington Disease; Long-Term Potentiation; Models, Neurological; Movement Disorders; Neural Pathways; Parkinson Disease; Signal Transduction; Synapses; Thalamus | 2001 |
[Mechanisms of effects of adenosine and dopamine on modification of synapses in striato-nigral and striato-pallidal neurons].
Topics: Adenosine; Animals; Dopamine; Dopamine Agonists; Dopamine Antagonists; Globus Pallidus; Huntington Disease; Motor Activity; Parkinson Disease; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A2A; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Purinergic P1; Substantia Nigra; Synapses; Synaptic Transmission | 2001 |
18 other study(ies) available for adenosine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Neuroprotective Activity of Curcumin in Combination with Piperine against Quinolinic Acid Induced Neurodegeneration in Rats.
Topics: Adenosine; Alkaloids; Animals; Antioxidants; Benzodioxoles; Brain; Catecholamines; Curcumin; Cytokines; Drug Therapy, Combination; gamma-Aminobutyric Acid; Glutamic Acid; Glutathione; Hand Strength; Huntington Disease; Lipid Peroxidation; Locomotion; Neuroprotective Agents; Nitrites; Piperidines; Polyunsaturated Alkamides; Quinolinic Acid; Rats, Wistar | 2016 |
Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Biomarkers; Corpus Striatum; Disease Models, Animal; Gene Expression Regulation; Humans; Huntingtin Protein; Huntington Disease; Locomotion; Nucleoside Transport Proteins; Prefrontal Cortex; Psychomotor Disorders; Purines; Rats; Rats, Transgenic; Receptor, Adenosine A2A; Triazines; Triazoles; Trinucleotide Repeat Expansion; Tritium | 2016 |
Changes in cardiac nucleotide metabolism in Huntington's disease.
Topics: Adenosine; Adenosine Deaminase; AMP Deaminase; Animals; Disease Models, Animal; Humans; Huntington Disease; Inosine; Mice; Myocardium; Purine-Nucleoside Phosphorylase; Pyrophosphatases | 2016 |
Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
Topics: Adenine; Adenosine; Animals; Corpus Striatum; Disease Models, Animal; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Humans; Huntingtin Protein; Huntington Disease; Indoles; Mice; Mice, Transgenic; Neostriatum; Trinucleotide Repeat Expansion | 2017 |
Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Cytoprotection; Disease Models, Animal; Enzyme Activation; Huntington Disease; Interneurons; Male; Mice; Mice, Transgenic; Neuroprotective Agents; Nitrergic Neurons; Nitric Oxide; Nitric Oxide Synthase Type I; Pyrimidines; Receptor, Adenosine A2A; Triazoles; Up-Regulation | 2008 |
The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Cell Line; Disease Models, Animal; Female; Humans; Huntington Disease; Liver; Male; Mice; Phenethylamines; Proteasome Endopeptidase Complex; Receptor, Adenosine A2A; Serotonin Plasma Membrane Transport Proteins; Ubiquitin; Urea | 2009 |
Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Blotting, Western; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Electrophysiology; Female; Huntington Disease; Male; Mice; Neurons; Phenethylamines; Protein Subunits; Receptors, N-Methyl-D-Aspartate; Statistics, Nonparametric | 2010 |
A new drug design targeting the adenosinergic system for Huntington's disease.
Topics: Adenosine; Animals; Disease Models, Animal; Drug Design; Drugs, Chinese Herbal; Equilibrative Nucleoside Transporter 1; Female; Humans; Huntington Disease; Male; Mice; Mice, Knockout; Models, Molecular; PC12 Cells; Peptides; Plant Extracts; Rats; Receptor, Adenosine A2A; Trinucleotide Repeat Expansion | 2011 |
The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.
Topics: Adenosine; Animals; Behavior, Animal; Binding, Competitive; Body Weight; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dystonia; Enkephalins; Hindlimb; Huntington Disease; In Vitro Techniques; Male; Mitochondria; Motor Activity; Neuroprotective Agents; Neurotoxins; Nitro Compounds; Propionates; Purinergic P1 Receptor Agonists; Rats; Rats, Inbred Lew; Reproducibility of Results; RNA, Messenger; Succinate Dehydrogenase; Synaptic Transmission; Treatment Outcome | 2002 |
A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists.
Topics: Adenosine; Animals; Body Weight; Cell Death; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Encephalitis; Genetic Predisposition to Disease; Glutamic Acid; Huntington Disease; Male; Mice; Mice, Knockout; Neuroprotective Agents; Nitro Compounds; Phenethylamines; Propionates; Rats; Rats, Inbred Lew; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Purinergic P1; RNA, Messenger; Signal Transduction; Survival Rate; Synapses; Xanthines | 2003 |
Adenosine A(2A) antagonism increases striatal glutamate outflow in the quinolinic acid rat model of Huntington's disease.
Topics: Adenosine; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Extracellular Space; Glutamic Acid; Huntington Disease; Male; Microdialysis; Models, Animal; Neuroprotective Agents; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinolinic Acid; Rats; Rats, Wistar; Receptor, Adenosine A2A; Time Factors; Triazoles | 2003 |
Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Dopamine; Drug Administration Routes; Drug Synergism; Electron Transport Complex II; gamma-Aminobutyric Acid; Huntington Disease; Male; Malonates; Mice; Mitochondria; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Theobromine; Tyrosine 3-Monooxygenase; Xanthines | 2003 |
Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Extracellular Fluid; Glutamic Acid; Huntington Disease; Male; Mice; Mice, Inbred CBA; Mice, Transgenic; Mitogen-Activated Protein Kinases; Pyrimidines; Receptor, Adenosine A2A; Triazoles | 2004 |
Neurotrophin survival signaling mechanisms.
Topics: Adenosine; Alzheimer Disease; Brain-Derived Neurotrophic Factor; Cell Survival; Hippocampus; Humans; Huntington Disease; Motor Neurons; Nerve Growth Factors; Neuropeptides; Neurotransmitter Agents; Pituitary Adenylate Cyclase-Activating Polypeptide; Prosencephalon; Receptor, trkA; Receptor, trkB; Receptors, G-Protein-Coupled; Signal Transduction | 2004 |
CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Brain; Disease Models, Animal; Huntington Disease; Male; Mice; Mice, Transgenic; Motor Activity; Phenethylamines | 2005 |
Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
Topics: Action Potentials; Adenosine; Adenosine A2 Receptor Agonists; Animals; Antihypertensive Agents; Corpus Striatum; Disease Models, Animal; Huntington Disease; Mice; Mice, Transgenic; Neuroprotective Agents; Neurotoxins; Organ Culture Techniques; Phenethylamines; Receptor, Adenosine A2A; Receptors, N-Methyl-D-Aspartate; Recovery of Function; Species Specificity; Synaptic Transmission | 2007 |
CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease.
Topics: Adenosine; Amphetamine; Animals; Disease Models, Animal; Huntington Disease; Male; Motor Activity; Phenethylamines; Quinolinic Acid; Rats; Rats, Wistar | 1994 |
Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease.
Topics: Adenosine; Aged; Aged, 80 and over; Animals; Basal Ganglia; Corpus Striatum; Female; Guinea Pigs; Humans; Huntington Disease; Male; Middle Aged; Nerve Degeneration; Organ Specificity; Oxidopamine; Parkinson Disease; Quinolinic Acid; Quinolinic Acids; Receptors, Purinergic | 1991 |